MA51902A - Schémas posologiques d'anticorps b7-h4 - Google Patents

Schémas posologiques d'anticorps b7-h4

Info

Publication number
MA51902A
MA51902A MA051902A MA51902A MA51902A MA 51902 A MA51902 A MA 51902A MA 051902 A MA051902 A MA 051902A MA 51902 A MA51902 A MA 51902A MA 51902 A MA51902 A MA 51902A
Authority
MA
Morocco
Prior art keywords
dosage schedules
antibodies dosage
antibodies
schedules
dosage
Prior art date
Application number
MA051902A
Other languages
English (en)
Inventor
Helen L Collins
Sandeep P Inamdar
Hong Xiang
Xiang Zhang
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of MA51902A publication Critical patent/MA51902A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA051902A 2018-02-21 2019-02-21 Schémas posologiques d'anticorps b7-h4 MA51902A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862633527P 2018-02-21 2018-02-21
US201962802100P 2019-02-06 2019-02-06

Publications (1)

Publication Number Publication Date
MA51902A true MA51902A (fr) 2021-05-26

Family

ID=65686103

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051902A MA51902A (fr) 2018-02-21 2019-02-21 Schémas posologiques d'anticorps b7-h4

Country Status (13)

Country Link
US (3) US20210070862A1 (fr)
EP (1) EP3755719A1 (fr)
JP (2) JP7258038B6 (fr)
KR (1) KR102863169B1 (fr)
CN (1) CN111868089B (fr)
AU (1) AU2019226009B2 (fr)
BR (1) BR112020016990A2 (fr)
CA (1) CA3091161A1 (fr)
IL (1) IL276623A (fr)
MA (1) MA51902A (fr)
MX (1) MX2020008730A (fr)
SG (1) SG11202007820QA (fr)
WO (1) WO2019165075A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020003533A2 (pt) * 2017-08-25 2020-11-17 Five Prime Therapeutics, Inc. anticorpos b7-h4 e métodos de uso dos mesmos
CN111741978A (zh) * 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
EP3759142A1 (fr) 2018-03-02 2021-01-06 Five Prime Therapeutics, Inc. Anticorps b7-h4 et leurs procédés d'utilisation
SG11202103153VA (en) * 2018-10-15 2021-04-29 Five Prime Therapeutics Inc Combination therapy for cancer
AU2022205057A1 (en) 2021-01-04 2023-07-13 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (fr) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
AU2001276842B2 (en) 2000-06-28 2007-04-26 Glycofi, Inc. Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
CA2424977C (fr) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Procede de purification d'un anticorps
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
CA2799805C (fr) 2002-03-19 2016-05-17 Stichting Dienst Landbouwkundig Onderzoek Optimisation du traitement du glycane chez les plantes
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
PL222222B1 (pl) 2003-01-22 2016-07-29 Glycart Biotechnology Ag Sposób wytwarzania polipeptydu
WO2007039818A2 (fr) 2005-05-09 2007-04-12 Glycart Biotechnology Ag Molecules de liaison a l'antigene possedant des zones fc modifiees et une liaison alteree aux recepteurs fc
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
US9676854B2 (en) * 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
WO2014100439A2 (fr) * 2012-12-19 2014-06-26 Amplimmune, Inc. Anticorps spécifiques de b7-h4 et compositions et procédés pour les utiliser
PH12019501393B1 (en) 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
CN107299085B (zh) * 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用
BR112020003533A2 (pt) * 2017-08-25 2020-11-17 Five Prime Therapeutics, Inc. anticorpos b7-h4 e métodos de uso dos mesmos
CN111741978A (zh) * 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂

Also Published As

Publication number Publication date
US20210070862A1 (en) 2021-03-11
AU2019226009A1 (en) 2020-09-03
JP2021513997A (ja) 2021-06-03
KR102863169B1 (ko) 2025-09-22
AU2019226009B2 (en) 2025-11-20
CA3091161A1 (fr) 2019-08-29
CN111868089A (zh) 2020-10-30
IL276623A (en) 2020-09-30
WO2019165075A1 (fr) 2019-08-29
JP2023089063A (ja) 2023-06-27
SG11202007820QA (en) 2020-09-29
BR112020016990A2 (pt) 2021-02-23
EP3755719A1 (fr) 2020-12-30
MX2020008730A (es) 2020-12-07
JP7258038B6 (ja) 2023-04-25
US20240317864A1 (en) 2024-09-26
KR20200123169A (ko) 2020-10-28
US20230287123A1 (en) 2023-09-14
CN111868089B (zh) 2025-08-22
JP7258038B2 (ja) 2023-04-14

Similar Documents

Publication Publication Date Title
EP3765522A4 (fr) Anticorps anti-claudine 18.2
MA52884A (fr) Anticorps anti-il-11
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA53434A (fr) Anticorps anti-tigit
MA52366A (fr) Anticorps anti-tl1a optimisés
EP3883970A4 (fr) Anticorps anti-b7-h3
MA49043A (fr) Formulation stable d'anticorps
MA51903A (fr) Formulations d'anticorps b7-h4
MA55600A (fr) Anticorps anti-ige
EP3299383A4 (fr) MODIFICATION SPÉCIFIQUE DE L'ANTICORPS PAR UN PEPTIDE DE LIAISON À IgG
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
EP3601604A4 (fr) Détection multiple d'anticorps spécifiques à un isotype
MA51902A (fr) Schémas posologiques d'anticorps b7-h4
MA54052A (fr) Formulation d'anticorps
EP3752536A4 (fr) Anticorps anti-her2
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
EP3831851A4 (fr) Anticorps anti-btla
MA52152A (fr) Anticorps
MA54139A (fr) Formulation d'anticorps
EP3995582A4 (fr) Anticorps anti-epha4
EP3613770A4 (fr) Anticorps monoclonal à pd-l1
EP3849612A4 (fr) Variants d'anticorps anti-vih 10-1074
EP3867272A4 (fr) Utilisation d'anticorps anti-fam19a5
EP3947466A4 (fr) Anticorps anti-hla-dq2.5
EP3852779A4 (fr) Anticorps anti-klrg1